

NUTRITION UNIT

Scientific Panel on Dietetic Products, Nutrition and Allergies

Draft Agenda of the 58th plenary meeting

08-10 April 2014, 9 am – 6 pm, Parma

11 April 2014, 9 am – 1 pm, Parma

- 1 Welcome and apologies for absence
- 2 Adoption of the agenda
- 3 Declarations of interest
- 4 Agreement of the minutes of the 57th Plenary meeting held on 05-07 February 2014
- 5 Report on written procedures since 57th Plenary meeting
- 6 Scientific outputs submitted for discussion and / or possible adoption

Applications pursuant to Article 14/13.5 of Regulation (EC) No 1924/2006

- 6.1 Biocodex - “**Citrulline-malate**” and “**improved recovery from muscle fatigue**” (Art. 13.5, 0394_BE, [EFSA-Q-2013-00659](#))

For possible adoption

- 6.2 Specialised Nutrition Europe (formerly IDACE) – “**Choline**” and “**development of brain**” (Art. 14, 0054_FR, [EFSA-Q-2008-134](#))

For possible adoption

- 6.3 Specialised Nutrition Europe (formerly IDACE) – “**Complex carbohydrates**” and “**contribution to satiety**” (Art. 14, 0051_FR, [EFSA-Q-2008-131](#))

For possible adoption

- 6.4 Specialised Nutrition Europe (formerly IDACE) – “**Zinc**” and “**normal function of the immune system**” (Art. 14, 0109_FR, [EFSA-Q-2008-189](#))

For possible adoption

- 6.5 Barry Callebaut Belgium NV - “**Cocoa flavanol**” and “**help maintain the elasticity of the blood vessels which contributes to normal blood flow**” (Art. 19, 0398_BE, [EFSA-Q-2013-00832](#))

For possible adoption

- 6.6 Comvita New Zealand Limited – “**Daily intake of supplemental olive leaf extract polyphenols**” and “**contributes to the reduction of the blood glucose rise after meals**” (Art. 13.5, 00397_UK, [EFSA-Q-2013-00783](#))

For possible adoption

- 6.7 Naturex SA – **“Cranberry extract named Pacran” and “inhibition of adhesion of P-fimbriated *E. Coli* to urinary tract cells”** (Art. 13.5, 0400_FR, [EFSA-Q-2013-00889](#))

For possible adoption

- 6.8 Jemo-pharm A/S - **“CranMax®” and “prevents adhesion of *E.coli* to uroepithelial cells which is a risk factor for developing urinary tract infections”** (Art. 14, 0391_DK, [EFSA-Q-2013-00649](#))

For possible adoption

- 6.9 PiLeJe – **“A combination of *B. longum* LA 101, *L. helveticus* LA 102, *L. lactis* LA 103 and *S. thermophilus* LA 104” and “reducing intestinal discomfort”** (Art. 13.5, 0401_FR, [EFSA-Q-2013-00892](#))

For possible adoption

- 6.10 PiLeJe – **“A combination of *B. longum* LA 101, *L. helveticus* LA 102, *L. lactis* LA 103 and *S. thermophilus* LA 104” and “improvement of stools frequency”** (Art. 13.5, 0402_FR, [EFSA-Q-2013-00893](#))

For possible adoption

- 6.11 Clasado Limited - **“Regular daily consumption of 1.37g galactooligosaccharides from Bimuno®” and “may reduce abdominal discomfort”** (Art. 13.5, 0406_MT, [EFSA-Q-2014-00022](#))

For discussion

Dietary Reference Values

- 6.12 **Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for iodine** ([EFSA-Q-2011-01213](#))

For discussion / possible adoption

- 6.13 **Draft technical report on the comments received during the public consultation for the draft DRVs for iodine** ([EFSA-Q-2013-01017](#))

For discussion / possible endorsement

- 6.14 **Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for zinc** ([EFSA-Q-2011-01233](#))

For discussion / possible endorsement for release for public consultation

- 6.15 **Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for chromium** ([EFSA-Q-2011-01209](#))

For discussion / possible endorsement for release for public consultation

- 6.16 **Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for folate** ([EFSA-Q-2011-01212](#))

For discussion / possible endorsement for release for public consultation

Novel Foods

- 6.17 **Draft Opinion on the safety of astaxanthin-rich ingredients (AstaREAL A1010 and AstaREAL L10) as Novel Food ingredients (Bioreal (Sweden) AB) ([EFSA-Q-2011-00990](#))**

For possible adoption

Others

- 6.18 **Draft opinion on health benefits of fish consumption ([EFSA-Q-2013-00167](#))**

For discussion / possible adoption

- 6.19 **Draft opinion on the evaluation of allergenic foods for labelling purposes ([EFSA-Q-2011-00760](#))**

For discussion / possible endorsement for release for public consultation

- 6.20 **Draft opinion on Safety assessment of caffeine ([EFSA-Q-2013-00220](#))**

For discussion / possible endorsement for release for public consultation

- 6.21 **Draft opinion on the composition of milk based-drinks and similar products intended for infants and young children ([EFSA-Q-2013-00264](#))**

For discussion / possible endorsement for release for public consultation

7 New mandates

- 7.1 Applications pursuant to Article 14/13.5 of Regulation (EC) no 1924/2006

- 7.2 Other mandates

8 Feedback from the Scientific Committee/the Scientific Panel, Working Groups, EFSA, the European Commission

- 8.1 Scientific Committee and other Scientific Panels

- 8.2 Working groups

- 8.3 EFSA

- 8.4 European Commission

9 Other scientific topics for information and/or discussion

10 Any other business